← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Oncoarendi Therapeutics, Llc
Groton, CT
$2,275,203
Total funding
3
Grants
Funding over time
peak $1.5M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,275,203 · 3
By mechanism
R44$1,730,420 · 1
R43$544,783 · 2
Investigators at Oncoarendi Therapeutics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of an Oral Acidic Mammalian Chitinase Inhibitor to Treat Asthma$1,505,420
R44 · FY2018 · HL
Myocardin-related transcription factor (MRTF) pathway modulators as a novel, disease-modifying oral medicine for idiopathic pulmonary fibrosis (IPF)$241,125
R43 · FY2024 · HL
Potent oral chitotriosidase-1 inhibitors as a novel therapy for sarcoidosis$237,200
R43 · FY2019 · HL
Development of an Oral Acidic Mammalian Chitinase Inhibitor to Treat Asthma$225,000
R44 · FY2016 · HL
Myocardin-related transcription factor (MRTF) pathway modulators as a novel, disease-modifying oral medicine for idiopathic pulmonary fibrosis (IPF)$66,458
R43 · FY2025 · HL